Impact of Rivastigmine on Caregiver Burden Associated with Alzheimer's Disease in Both Informal Care and Nursing Home Settings

Author： Grossberg George T.  

Publisher： Adis International

ISSN： 1170-229X

Source： Drugs & Aging, Vol.25, Iss.7, 2008-01, pp. : 573-584

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Metrifonate in Alzheimer's disease: less caregiver burden

By  

Inpharma, Vol. 1, Iss. 1235, 2000-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Long-Term Effects of Rivastigmine Treatment on the Need for Psychotropic Medications in Nursing Home Patients with Alzheimer’s Disease: Results of a 52-Week Open-Label Study

By Edwards Keith  

Clinical Drug Investigation, Vol. 25, Iss. 8, 2005-01 ,pp. : 507-515

Adis International

Access to resources Recommend Favorite

Impact of Rivastigmine Use on the Risk of Nursing Home Placement in a US Sample

By Kathleen M. Beusterien  

CNS Drugs, Vol. 18, Iss. 15, 2004-01 ,pp. : 1143-1148

Adis International

Access to resources Recommend Favorite

Assessment, Measures and Approaches to Easing Caregiver Burden in Alzheimer's Disease

By Farcnik K.   Persyko M.S.  

Drugs & Aging, Vol. 19, Iss. 3, 2002-01 ,pp. : 203-215

Adis International

Access to resources Recommend Favorite

Drug Treatments for Alzheimer's Disease: Shifting the Burden of Care

By Max W.  

CNS Drugs, Vol. 11, Iss. 5, 1999-05 ,pp. : 363-372

Adis International

Access to resources Recommend Favorite